Article
Multibillion Spent on Drug Development, But Is It Helping?
While the pharmaceutical industry has always justified the billions spent on developing a candidate drug molecule, the process has definitely seen some important changes. This article evaluates whether these revolutionary changes have influenced drug development for the better.
In November 2014, Tufts Center for Drug Discovery announced it takes $2.6 billion to push a drug through development and marketing approval—a process that often spans longer than 10 years.
This eye-opening amount of time and money was, of course, met with some skepticism from consumer groups and the media, which argued that the Tufts research—partially funded by drug makers—could simply be trying to justify rising drug prices. (Both The Wall Street Journal blog and The New York Times published pieces highlighting the ways critics approached the news release.)
But critics aside, it’s figures such as these that are inspiring the industry to find new ways to speed drug development. The solutions will vary depending on the type of treatment and the resources available to the companies developing these drugs.
Read the complete article at Bioprocess Online: http://bit.ly/1BSzJJB
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
